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A major mechanism of action of nonsteroidal anti-inflammatory drugs (NSAIDs) is
the lowering of prostaglandin (PG) production through inhibition of the cyclooxygenase
(COX) enzyme, which catalyzes the conversion of arachidonic acid into PG (1). Since PG
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In the present study, a series of benzothiazol derivatives 3a-l
containing pyrazolo[3,4-d]pyrimidine moiety at the second
position were synthesized and characterized by analytical and
spectral data. The compounds were tested for their in vitro
antimicrobial activity. Compounds 1-(1,3-benzothiazol-2-
yl)-3-methyl-4-phenyl-1H-pyrazolo[3,4-d]pyrimidine (3a), 1-
(1,3-benzothiazol-2-yl)-4-(4-chlorophenyl)-3-methyl-1H-py-
razolo[3,4-d]pyrimidine (3d) and 1-(1,3-benzothiazol-2-yl)-
3-methyl-4-substituted phenyl-1H-pyrazolo[3,4-d]pyrimidi-
nes (3h-j) showed significant inhibitory activity against P.






midin-4-yl]-N,N-dimethylaniline (3j) and 1-(1,3-benzothia-
zol-2-yl)-3-methyl-4-[2-phenylvinyl]-1H-pyrazolo[3,4-d]pyri-
midine (3k) were found to be active against C. albicans.
Some of these synthesized compounds were evaluated for
their in vivo acute toxicity, analgesic, anti-inflammatory, and
ulcerogenic actions. The tested compound 4-[1-(1,3-benzo-
thiazol-2-yl)-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-N,
N-dimethylaniline (3j) exhibited maximum analgesic and
anti-inflammatory activities. Compounds 1-(1,3-benzothiazol-
-2-yl)-3-methyl-4-(3-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimi-
dine (3i) and 3j showed a significant gastrointestinal protec-
tion compared to the standard drug diclofenac sodium.
Keywords: benzothiazoles, pyrazolo[3,4-d]pyrimidine, anti-
microbial activity, anti-inflammatory activity
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has a dual function, mediation of inflammation (2) and cytoprotection (3) in the stomach
and intestine, long-term usage of NSAIDs to relieve the symptoms of inflammation and
pain always results in gastrointestinal (GI) disorders and renal toxicity (4). It is known
that bacterial infections often produce pain and inflammation. In normal practice,
chemotherapeutic, analgesic, and anti-inflammatory drugs are prescribed simulta-
neously, which increases the risk of developing NSAIDs-related complications, especial-
ly in the elderly, patients with a prior history of peptic ulcer disease and patients with
impaired kidney functions. Hence, there is a pressing need for drugs having both anti-
microbial and analgesic/anti-inflammatory activities with minimum adverse effects.
Pyrazolo[3,4-d]pyrimidine and related fused heterocycles are of interest as potential
bioactive molecules and have received a great deal of attention due to their useful anti-
bacterial (5), antifungal (6) and anti-inflammatory (7) properties. In addition, many ben-
zothiazole derivatives exhibit a wide variety of biological activities [antimicrobial (8, 9)
and anti-inflammatory (10, 11)]. Based on the above observations and with the aim of
developing new dual acting antimicrobial/anti-inflammatory agents with minimum ul-
cerogenic effects, it appeared of interest to link the benzothiazole nucleus at the second
position to some pyrazolo[3,4-d]pyrimidine moiety. This is an attempt to investigate the
influence of such hybridization and structure variation on the anticipated biological ac-
tivities, hoping to add some synergistic biological significance to the target molecules. In
the present investigation, we aimed to synthesize novel benzothiazole incorporated py-
razolo[3,4-d]pyrimidine derivatives and evaluate their antimicrobial, analgesic, anti-in-
flammatory and ulcerogenic activities.
EXPERIMENTAL
Requisite chemicals were of reagent grade and were purified when necessary. Melt-
ing points were determined in open glass capillaries and are uncorrected. The reaction
progress was routinely monitored by thin layer chromatography (TLC) on silica gel pla-
tes (Merck 60 F254, Germany). The IR spectra were recorded on a Shimadzu 8400S FT-IR
spectrometer (Japan) in KBr pellets and band positions are given in reciprocal centime-
ters (cm–1). The 1H NMR and 13C NMR spectra were recorded using a Bruker AV-III 400
spectrometer (Germany) with dimethyl sulfoxide (DMSO)-d6 as solvent. Chemical shifts
were reported in ppm using the solvent as internal standard. Mass spectra were mea-
sured on a Shimadzu LC-MS 2010A mass spectrometer (Japan) equipped with a manual
injector, a photodiode array detector, an electrospray ionization source and a single-qua-
drupole mass analyzer in both positive and negative ion modes. Elemental analyses were
carried out on a Flash EA 1112 series instrument (Thermo Finnigan, Italy).
2-Hydrazino-1,3-benzothiazole (1) and 1-(1,3-benzothiazol-2-yl)-3-methyl-1,4-dihy-
dro-5H-pyrazol-5-one (2) were prepared by the procedure described in the literature (12,
13).
Synthesis of 1-(1,3-benzothiazol-2-yl)-3-methyl-4-substituted phenyl-1H-pyrazolo[3,4-d]pyri-
midine derivatives (3a-l). General procedure
A mixture of 1-(1,3-benzothiazol-2-yl)-3-methyl-1,4-dihydro-5H-pyrazol-5-one (2)
(10 mmol, 2.31 g), urea (10 mmol, 0.60 g) and appropriate araldehyde (10 mmol, for
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benzaldehyde 1.06 g, 2,3 or 4-chlorobenzaldehyde 1.40 g, 2 or 4-hydroxybenzaldehyde
1.22 g, 4-methoxybenzaldehyde 1.36 g, 3,4-dimethoxybenzaldehyde 1.66 g, 3-nitrobenz-
aldehyde 1.51 g, 4-dimethylaminobenzaldehyde 1.49 g, cinnamaldehyde 1.32 g, 2-furfur-
aldehyde 0.96 g) in absolute ethanol (30 mL) was heated under reflux on a water bath for
7–8 h. The mixture was concentrated in vacuo and cooled to room temperature. The sepa-
rated solid was filtered, washed several times with water, dried and recrystallized from
appropriate solvent to give the title compounds 3a-l.
Physicochemical and spectral data for the synthesized compounds are given in Ta-
bles I and II. Synthetic route is represented in Scheme 1.
Solvent for crystallization: for 3a, 3c-f, 3h, 3i acetone, for 3b, 3j chloroform and me-
thanol 1:1, for 3g, 3l methanol, for 3k chloroform and petroleum ether 1:1
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Table I. Physicochemical properties of the synthesized compounds 3a-l
Compd. Ar
Formula Yield M.p. Analysis (calcd./found, %)
























































M. A. Azam et al.: Synthesis and biological evaluation of some novel pyrazolopyrimidines incorporating a benzothiazole ring system,


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Antimicrobial activity. – Standard strains were procured from the National Collection
of Industrial Microorganism, National Chemical Laboratory, India. Synthesized com-
pounds 3a-l were tested [50 and 100 µg mL–1 in sterile dimethyl sulfoxide (DMSO)] for
their in vitro antimicrobial activity by the cup plate diffusion method (14). The anti-
bacterial activity was evaluated on nutrient agar (Hi-media) plates (37 °C, 24 h) against
Gram-positive bacteria Staphylococcus aureus NCIM 2079, Bacillus megaterium NCIM 2187,
Gram-negative bacteria Escherichia coli NCIM 2567 and Pseudomonas aeruginosa NCIM 2036.
Test compounds were also evaluated for their antifungal potential on Sabouraud dex-
trose agar (Hi-media) plates (26 °C, 48–72 h) against Candida albicans NCIM 3100. Cipro-
floxacin and ketoconazole were used as control drugs as 10 and 20 µg mL–1 solutions,
respectively, in sterile dimethyl sulfoxide. Average diameter of inhibition zone (three in-
dependent evaluations) of bacterial or fungal growth around the disk in mm (Table III)
were recorded.
Animals. – Experimental animals were procured from the M/S Venkatesh Enterpri-
ses, India. The animals were fed a standard rodent diet (Hindustan Liver Ltd., India)
with water ad libitum and were housed in rooms maintained at 23 ± 2 °C with a 12 h
light/dark cycle and relative humidity 45–50 %. The Animal Ethics Committee of the J.
S. S. College of Pharmacy, Ootacamund, India, approved all experimental protocols, in
accordance with the Indian Government Legislation on Animal Care. Synthesized com-
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Ar = C6H5; 2-Cl-C6H4; 3-Cl-C6H4; 4-Cl-C6H4; 2-OH-C6H4; 4-OH-C6H4; 4-OCH3-C6H4



































pounds 3a–l were evaluated for their acute toxicity, analgesic and anti-inflammatory ac-
tivities. Data were statistically analyzed by one-way analysis of variance (ANOVA) fol-
lowed by Student’s t-test to assess the statistical significance.
Acute toxicity. – Acute oral toxicity was checked for compounds 3a-l following the
Organization of Economic Cooperation and Development (OECD-423) guidelines (15)
(acute toxic class method). Swiss albino mice (n = 3) of either sex (38–45 g), selected by
random sampling, were used for the study. The animals were fasted for 3–4 h with water
ad libitum, after which the test compounds were administered orally as a suspension in 1 %
carboxymethylcellulose (CMC) (m/V, in water) at doses of 50, 100, 250, 500 and 1000 mg kg–1
body mass. The mice were observed for three days.
Analgesic activity by acetic acid induced writhing method. – Analgesic activity of the
synthesized compounds was evaluated by the acetic acid induced writhing method (16)
using Swiss albino mice (n = 6) of either sex (35–48 g). The test compounds and diclofenac
sodium were suspended in 1.0 % CMC and administered orally. One hour after adminis-
tration of the test compounds, 0.10 mL acetic acid solution (1.0 %, m/V, in sterile saline)
was injected intraperitoneally and stretching movements comprising of arching of the
back, body elongation and extension of hind limbs were counted for 15 min. The analge-
sic activity was expressed in terms of percentage inhibition (Table IV).
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Table III. Antimicrobial activity of synthesized compounds 3a-l a
Compd.











3a 13 – 19 23 16
3b 13 – 17 19 24
3c – – 18 19 22
3d 12 12 21 27 18
3e 12 – 20 19 24
3f 13 12 19 19 23
3g 11 – 21 18 22
3h 13 – 19 23 26
3i 12 13 21 24 21
3j 12 12 22 22 26
3k 13 – 19 18 24
3l 12 12 21 23 13
Ciprofloxacin 30 35 41 50 –
Ketoconazole – – – – 32
DMSO – – – – –
– no activity.
a Average of three independent determinations. Concentration tested: compounds 3a-l 100 µg mL–1,
ciprofloxacin 10 µg mL–1, ketoconazole 20 µg mL–1.
Analgesic activity by Eddy’s hot plate method. – Analgesic activity of the synthesized
compounds was also evaluated by Eddy’s hot plate method (17) using Swiss albino mice
(n = 6) of either sex (44–52 g). The test compounds and paracetamol were administered
orally suspended in 1.0 % CMC. One hour after administration of the test compounds,
animals were individually placed on hot plate maintained at 55 ± 0.5 °C. The response
time was noted as the time at which animals reacted to the pain stimulus either by paw
licking or jump response, whichever appeared first. The reaction time in control and
treated animals was recorded at 0.5, 1, 2 and 3 h after the treatment. The cut off time for
the reaction was 15 seconds. Results are presented in Table V.
Anti-inflammatory activity. – The acute anti-inflammatory activity of the synthesized
compounds was determined following the carrageenean induced paw oedema method
(18) in Wistar albino rats (n = 6) of either sex (155–180 g). The animals were fasted for 24 h
before the experiment with free access to water. The test compounds and diclofenac
sodium were administered orally as a suspension in 1.0 % CMC. Control rats received
appropriate volumes of 1.0 % CMC solution orally. Thirty minutes after administration
of the test compounds, 0.1 mL carrageenean solution (1.0 %, m/V, in sterile saline) was
injected into the sub-plantar tissue of the right hind paw of each rat. Paw volume was
measured at time intervals of 0.5, 1, 2 and 3 h after carrageenean injection by means of a
plethysmometer (UGO Basile 7140, India). The anti-inflammatory activity results are
summarized in Table VI.
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Table IV. Analgesic activity of some selected compounds in mice by the acetic induced writhing method





41.7 ± 1.3c 37.3 ± 0.8c 55.2 ± 1.2c 56.3 ± 1.2d 59.6 ± 0.9c 36.6 ± 0.6b 62.6 ± 1.3c
Test compounds and diclofenac sodium were tested at 0.30 and 0.06 mmol kg–1 body mass, respectively.
a Mean ± SEM, n = 6.
Significance levels compared to the control: b p < 0.05, c p < 0.01 and d p < 0.001.
Table V. Analgesic activity of some selected compounds in mice by Eddy’s hot plate method
Compd.
Analgesic activitya
0.5 h 1 h 2 h 3 h
3a 32.1 ± 0.9c 60.3 ± 1.2d 39.7 ± 0.8c 24.6 ± 1.0c
3d 30.8 ± 0.9c 64.4 ± 1.0c 51.5 ± 1.2c 26.1 ± 1.2d
3h 50.0 ± 1.1c 73.2 ± 1.1c 75.0 ± 1.5b 61.4 ± 1.0c
3i 58.4 ± 1.3c 43.4 ± 0.8c 35.1 ± 1.1d 27.0 ± 1.1d
3j 40.4 ± 1.3c 54.9 ± 1.2d 51.7 ± 1.1c 39.6 ± 0.9b
3l 49.8 ± 1.2d 51.7 ± 1.2b 67.5 ± 1.1c 61.6 ± 1.3c
Paracetamol 61.3 ± 1.0c 70.2 ± 0.9c 86.9 ± 0.8c 58.7 ± 0.7c
Test compounds and paracetamol were tested at 0.30 and 0.66 mmol kg–1 body mass, respectively.
a Mean ± SEM, n = 6.
Significance levels compared to the respective control: b p < 0.05, c p < 0.01 and d p < 0.001.
Ulcerogenic effects. – Test compounds 3e, 3h and 3j were evaluated for their acute
ulcerogenic effects according to the method of Cioli et al. (19) using Wistar albino rats
(n = 6) of either sex (175–190 g). The test compounds and diclofenac sodium were ad-
ministered orally as a suspension in 1 % CMC solution. Control group received appro-
priate volumes of CMC solution orally. Food, but not water, was removed 24 h before
administration of the test compounds. After compound treatment, the rats were fed a
standard diet for 17 h and then sacrificed. Their stomachs were removed, cut out along
the greater curvature, washed with distilled water and then gently cleaned by dipping
in normal saline. Mucosal damage was examined by means of a magnifying glass. For
each stomach, the mucosal damage was assessed according to the following scoring sys-
tem: 0.5 redness; 1.0 spot ulcers; 1.5 hemorrhagic streaks; 2.0 ulcers > 3 but  5; 3.0 ulcers
> 5 (20). The mean score of each treated group minus the mean score of the control group
was regarded as the severity index of gastric mucosal damage. Results are presented in
Table VII.
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30 min 1 h 2 h 3 h
3a 17.0 ± 0.9b 36.7 ± 0.7b 38.4 ± 0.8c 27.2 ± 1.1c
3d 12.5 ± 1.1d 14.8 ± 1.2d 21.7 ± 1.2d 30.0 ± 1.1b
3h 13.3 ± 1.3c 20.7 ± 0.8d 41.6 ± 1.0c 35.9 ± 0.7c
3i 44.6 ± 1.2c 29.1 ± 1.1c 28.4 ± 1.3c 23.9 ± 1.2c
3j 56.8 ± 1.0d 67.7 ± 1.2b 74.7 ± 1.0d 47.6 ± 0.7d
3l 19.5 ± 1.1b 29.5 ± 1.4b 17.6 ± 1.3c 17.5 ± 1.1b
Diclofenac sodium 29.9 ± 1.2d 49.3 ± 0.9b 61.1 ± 1.2c 72.0 ± 0.9d
Test compounds and diclofenac sodium were tested at 0.30 and 0.06 mmol kg–1 body mass, respectively.
a Mean ± SEM, n = 6.
Significance levels compared to the respective control: b p < 0.05, c p < 0.01 and d p < 0.001.
Table VII. Ulcerogenic activity of some selected compounds





1.1 ± 0.8d 3.7 ± 0.7b 3.5 ± 1.2c 3.0 ± 0.9c 6.1 ± 1.1c
Test compounds and diclofenac sodium were tested at 0.60 and 0.12 mmol kg–1 body mass, respectively.
a Mean ± SEM, n = 6.
Significance levels compared to the control: b p < 0.05, c p < 0.01 and d p < 0.001.
RESULTS AND DISCUSSION
The synthetic route for the preparation of title compounds 3a-l is outlined in Sche-
me 1. The intermediate 2-hydrazino-1,3-benzothiazole (1) was prepared (12) by refluxing
2-mercaptobenzothiazole with hydrazine hydrate in water. 1-(1,3-Benzothiazol-2-yl)-3-
methyl-1,4-dihydro-5H-pyrazol-5-one (2) was prepared (13) by the treatment of com-
pound (1) with ethyl acetoacetate in boiling ethanolic potassium hydroxide. Further con-
densation of compound (2) with urea and araldehydes in refluxing absolute alcohol fur-
nished the corresponding title compounds 1-(1,3-benzothiazol-2-yl)-3-methyl-4-substituted
phenyl-1H-pyrazolo[3,4-d]pyrimidine (3a-l) in 61–72 % yield. Structures of the newly
synthesized compounds were confirmed by analytical and spectral data.
The infrared spectra of compounds (3a-l) revealed absorption bands within 2986–
2965 cm–1 for CH3, 1647–1610 cm–1 for C=N and 763–752 cm–1 for C-S-C stretch. Forma-
tion of pyrazolopyrimidine ring in 3i was supported by its 1H NMR spectrum (21), which
showed a singlet signal at d 8.19 ppm due to the CH=N fragment of the pyrazolopyrimi-
dine ring. Two multiplet signals that appeared at d 8.13–7.60 and 7.58–7.19 ppm were as-
signed to four aromatic protons each. Furthermore, the signal for the CH3 fragment was
ascribed to a singlet at d 2.45 ppm. Its mass spectrum showed an M+2 peak at m/z 390,
which is in conformity with the molecular formula C19H12N6O2S. It exhibited a base peak
at m/z 232 due to the C11H10N4S+ fragment, which is consistent with the structure of this
compound 3i. In the 13C NMR spectrum of compound 3i, azomethine carbon of the ben-
zothiazole ring resonated as a singlet signal at d 152.28 ppm, whereas two signals observ-
ed at d 151.13 and 150.66 ppm were assigned to azomethine carbons of the pyrimidine
ring. The C=N fragment of the pyrazole ring exhibited a signal at d 150.37 ppm. The ap-
pearance of signals between 148.18-123.44 ppm supported the presence of fourteen sp2
carbon atoms. A signal at 32.98 ppm was assigned to the CH3 fragment.
In vitro antimicrobial activity of synthesized compounds by the cup plate method
(14) was first tested at 50 µg mL–1concentration, but all compounds failed to produce the
antimicrobial effect against the tested microorganisms. However, at 100 µg mL–1, tested
compounds 3a, 3d, 3h-j and 3l displayed significant inhibitory activity (inhibition zone
22–27 mm, Table III) against Pseudomonas aeruginosa, whereas the other compounds
showed moderate activity (inhibition zone 18–22 mm) against the same organism. In this
regard, compound 3d with 4-Cl-C6H4 group at the fourth position of the pyrazolopy-
rimidine ring showed the highest activity (inhibition zone 27 mm). When the position of
the chloro substituent group was changed either to the second (3b) or third position (3c) in
the phenyl ring, a marked decrease in activity against P. aeruginosa was observed. It was
also observed that substitution with 2-OH-C6H4 (3e), 4-OH-C6H4 (3f) or CH=CH-C6H5
(3k) groups at the fourth position of the pyrazolopyrimidine ring resulted in a marked de-
crease in activity against the same microorganism. All the tested compounds exhibited
either moderate or weak inhibitory activity against Escherichia coli, Staphylococcus aureus
and Bacillus megaterium.
Antifungal screening revealed moderate to weak inhibitory activity against Candida
albicans. In this regard, compounds with 3,4-di-(OCH3)2 (3h) or 4-N(CH3)2 (3j) bulky groups
in the phenyl ring present at the fourth position of the pyrazolopyrimidine ring exhibited
maximum activity (inhibition zone 26 mm in both cases). In the present investigation, ac-
tivities of the tested compounds were much weaker than that of the standard drug.
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Compounds 3h-j showed significant inhibition against the acetic acid induced
writhing (55.2–59.6 %), compared to the reference drug diclofenac sodium (62.6 % inhi-
bition at a dose of 0.06 mmol kg–1 body mass). In this regard, highest activity (59.6 %
inhibition) was observed for compound 3j. It was also observed that compounds with C6H5
(3a), 4-Cl-C6H4 (3d) or 2-furyl (3l) groups at the fourth position of the pyrazolopyrimi-
dine ring resulted in a marked decrease in analgesic activity (36.6–41.7 % inhibition). It
is evident that substitution of 3-NO2-C6H4, 4-N(CH3)2-C6H3 or 3,4-(OCH3)2-C6H3 (in 3i,
3j and 3h) bulky groups in the phenyl ring present at the fourth position of the pyra-
zolopyrimidine ring is optimal for inhibition against the acetic acid induced writhing.
However, all the tested compounds were found to be significantly less potent compared
to the standard drug.
Analgesic activity of the synthesized compounds was also evaluated by Eddy’s hot
plate method (17). Screening results at the 0.30 mmol kg–1 (body mass) dosage are sum-
marized in Table V. Derivatives 3h, 3i and 3l exhibited fast analgesic activity (49.8–58.4
% analgesia), as evident from the observation at 30 min following oral administration
(0.30 mmol kg–1). After 1 h, compound 3h with 3,4-(OCH3)2-C6H3 group at the fourth
position of the pyrazolopyrimidine ring showed maximum activity (73.2 % analgesia)
compared to the reference drug paracetamol (70 % analgesia at 0.66 mmol kg–1), while
after 2 and 3 h compounds 3h and 3l showed marked activity (61.4–75.0 % analgesia)
against thermal stimuli compared to the reference drug (86.9 and 58.7 % analgesia, re-
spectively). It is evident from the results that the presence of either C6H4 or 3-NO2-C6H4
group markedly decreased the analgesic activity. It is also important to note that, except
for compounds 3h and 3l, a marked decrease in analgesic activity was observed after 3 h
following oral administration of test compounds. The promising analgesic activity
shown by compounds 3h and 3j in both models indicated that these compounds might
possess centrally and peripherally mediated analgesic properties.
At first, the anti-inflammatory activity of the synthesized compounds was studied (18)
at a 0.15 mmol kg–1 body mass dose, but it failed to affect the oedematogenic response.
The anti-inflammatory activity results determined at the 0.30 mmol kg–1 b.m. dosage are
summarized in Table VI. Compounds 3f and 3j showed a rapid onset of action (44.6 and
56.8 % inhibition, respectively), as evident from the observation 30 min after carrageenean
injection. After 1 h, maximum activity (67.7 % protection) was observed in compound 3j
having 4-N(CH3)2-C6H4 group at the fourth position of the pyrazolopyrimidine ring and
after 2 h compound 3j exhibited potent activity (74.7 % protection) when compared to the
reference drug diclofenac sodium (61.1 % at 0.06 mmol kg–1 b.m.). In general, a sharp de-
cline in anti-inflammatory activity was observed 3 h after carrageenean injection. The
other compounds showed moderate to weak activity (12.5–35.9 % inhibition) at all time
points and were less potent compared to the standard drugs.
Carrageenean-induced oedema is a biphasic response. The first phase is mediated
through the release of histamine, serotonin and kinins, whereas the second phase is re-
lated to the release of prostaglandin and slow reacting substances with peaks at 3 h (21,
22). In the present study, previous oral treatment with the test compounds was effective
in reducing the carrageenean induced paw oedema in rats between 30 min and the sec-
ond hour after the injection. This suggests that the compounds probably inhibited the re-
lease of histamine, serotonin and kinins in the first phase.
28
M. A. Azam et al.: Synthesis and biological evaluation of some novel pyrazolopyrimidines incorporating a benzothiazole ring system,
Acta Pharm. 63 (2013) 19–30.
Compounds 3h-j were evaluated for their ulcerogenic potential in rats according to
the method reported by Cioli et al. (19). The results indicated low ulcerogenic potential
of the tested compounds (severity index 2.5–3.7). The lowest reduction in ulcerogenic
potential (severity index 3.0) was observed for compound 3j (Table VII). The other tested
compounds, 3h and 3i, also exhibited a better gastrointestinal safety profile (severity in-
dex 3.7 and 3.5, respectively) compared to the standard drug diclofenac sodium (sever-
ity index 6.1).
No behavioral changes in animals were observed during the experiment and at the
end hematological parameters were estimated and there were no observable changes. In
the present study mortality was not observed and the tested compounds were well tolera-
ted by the experimental animals up to 1000 mg kg–1.
CONCLUSIONS
In summary, various benzothiazole derivatives were prepared with the objective of
developing dual antimicrobial-anti-inflammatory agents with minimum ulcerogenic ef-
fects. Among these compounds, 4-[1-(1,3-benzothiazol-2-yl)-3-methyl-1H-pyrazolo[3,4-
d]pyrimidin-4-yl]-N,N-dimethylaniline (3j) showed the most prominent and consistent
activity and the lowest ulcerogenicity. Therefore, compound 3j could represent a fruitful
matrix for the development of a new class of dual antimicrobial-anti-inflammatory
agents.
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